Last reviewed · How we verify

NCT03942497

Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America

Completed Last updated 12 February 2026
What this trial tests

trial in Recurrent/Metastatic Urothelial Cancers in 218 participants. Completed in 28 February 2022.

Timeline
1 August 2019
Primary endpoint
31 August 2021
28 February 2022

Quick facts

Lead sponsorLatin American Cooperative Oncology Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment218
Start date1 August 2019
Primary completion31 August 2021
Estimated completion28 February 2022
Sites9 locations across Brazil

Conditions studied

Sponsor

Latin American Cooperative Oncology Group

Who can join

18 and older, any sex, with Recurrent/Metastatic Urothelial Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Latin American Cooperative Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942497.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing